<DOC>
	<DOCNO>NCT01300026</DOCNO>
	<brief_summary>This multi-center , phase 1 , open-label first-in-human study AMG 319 subject relapse refractory lymphoid malignancy . This study consist two part . The dose exploration part 1 , study cohorts 3 subject relapse refractory lymphoid malignancy use practical continuous reassessment model [ CRM ] guide dose escalation define MTD . The dose expansion part 2 enroll 20 subject CLL dose high MTD explore safety , PK , clinical activity AMG 319 patient population .</brief_summary>
	<brief_title>AMG 319 Lymphoid Malignancy FIH</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Part 1 ( Dose Exploration ) : Relapsed refractory lymphoid malignancy follow type standard treatment exist longer effective : Bcell Chronic Lymphocytic Leukemia ( CLL ) confirm immunophenotype NonHodgkin Lymphoma : Low intermediate grade Bcell NHL , mantle cell lymphoma , noncutaneous Tcell NHL confirm histology and/or immunophenotype Part 2 ( Dose Expansion ) : Subjects must relapse refractory Bcell Chronic Lymphocytic Leukemia confirm immunophenotype standard treatment exist longer effective . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Life expectancy &gt; 3 month , opinion investigator Men woman ≥ 18 year old Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ( unless due diseaserelated bone marrow involvement document bone marrow biopsy , ≥ 0.5 x 109/L ) Platelet count ≥ 50 x 109/L ( without transfusion within 14 day enrollment ) Hemoglobin ≥ 9 g/dL Hepatic function , follow : Aspartate aminotransferase ( AST ) &lt; 3.0 x ULN Alanine aminotransferase ( ALT ) &lt; 3.0 x ULN Alkaline phosphatase ( ALP ) &lt; 2.0 x ULN ( &lt; 5 x ULN subject PI sponsor agree clinical data suggest extrahepatic source elevation ) Total bilirubin &lt; 1.5 x ULN ( &lt; 3.0 x ULN subject document Gilbert 's Disease indirect bilirubin level suggest extrahepatic source elevation ) Amylase ≤ 2.0 x IULN Lipase ≤ 2.0 x IULN Primary disseminate tumor involve central nervous system ( CNS ) A history malignancy , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer , solid tumor curatively treat evidence disease ≥ 2 year History allogeneic stemcell ( organ ) transplantation Clinically significant ECG change obscure ability ass PR , QT , QRS interval ; congenital long QT syndrome QTcF interval &gt; 470 msec Active chronic hepatitis B hepatitis C infection , determine serologic test Recent infection require intravenous antiinfective treatment complete ≤ 14 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Low intermediate grade B cell Lymphoma</keyword>
	<keyword>Non-cutaneous T-cell NHL</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>PI3K delta</keyword>
	<keyword>Lymphoid</keyword>
	<keyword>NHL</keyword>
	<keyword>MCL</keyword>
	<keyword>Hematologic</keyword>
	<keyword>CLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>